Stock Financial Ratios, Dividends, Split History

YGYI / Youngevity International, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price3.46
Volume2,500.00
Market Cap ($M)74.51
Enterprise Value ($M)72.41
Book Value ($M)15.44
Book Value / Share0.72
Price / Book5.60
NCAV ($M)-27.03
NCAV / Share-1.25
Price / NCAV-2.70
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 19,751,892
Common Shares Outstanding 19,728,772
Weighted Average Number Of Shares Outstanding Basic 19,672,445
Weighted Average Number Diluted Shares Outstanding Adjustment 79,447
Weighted Average Number Of Shares Outstanding Diluted 19,672,445
Preferred Stock Shares Outstanding 161,135
Common Stock Shares Outstanding 19,723,285
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.47
Return on Assets (ROA)-0.19
Return on Equity (ROE)-0.67
Balance Sheet (mrq) ($M)
Assets78.76
Liabilities63.32
Quick Ratio0.33
Current Ratio0.92
Income Statement (mra) ($M)
Revenues165,696,000.00
Operating Income-5.88
Net Income-12.68
Earnings Per Share Basic-0.65
Earnings Per Share Diluted-0.68
Cash Flow Statement (mra) ($M)
Cash From Operations-2.77
Cash from Investing-0.98
Cash from Financing-0.98
Identifiers and Descriptors
CUSIP987537107
Central Index Key (CIK)1569329

Split History

Stock splits are used by Youngevity International, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Youngevity International's (YGYI) CEO Steve Wallach on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
During this call, we will be making forward-looking statements regarding Youngevity's current expectations and projections about future events. Generally the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, including those set forth in Youngevity's filings with the SEC many of which are difficult to predict. (1-0)

Youngevity International's (YGYI) CEO Steve Wallach on Q4 2017 Results - Earnings Call Transcript

2018-03-29 seekingalpha
[Abrupt Start] …forward-looking statements contained on this conference call on account of new information, future events, or otherwise, except as required by law. (1-0)

CUSIP: 987537107